BHST

$4.37-0.20 (-4.47%)

Market OpenAs of Mar 17, 6:54 PM UTC

BioHarvest Sciences Inc.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$4.37
Potential Upside
5%
Whystock Fair Value$4.58
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorConsumer Defensive
IndustryPackaged Foods

BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through Nutraceuticals and Pharmaceuticals segments. The company develops botanical synthesis platform technology to produce plant cells with hi...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$98.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.41
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-200.22%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.02

Recent News

Proactive
Mar 5, 2026

Dow Jones sheds almost 800 points, oil prices climb as conflict continues in Middle East

The mood in the tech sector may get a lift from strong results from Broadcom, the ninth-largest company on the S&P 500

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Proactive
Mar 5, 2026

BioHarvest appoints former Israeli health chief Hezi Levy to board

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Thursday that it has appointed former Israeli health ministry chief Hezi Levy to the board effective immediately. David Tsur will step down from its board of directors after more than four years of service, the company said in a...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 16, 2026

BioHarvest Sciences Inc. (NASDAQ:BHST): Is Breakeven Near?

With the business potentially at an important milestone, we thought we'd take a closer look at BioHarvest Sciences...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Jan 23, 2026

Is BioHarvest Sciences (BHST) a Long-Term Compounder?

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the Russell 2000 Index during the fourth quarter as well as in FY2025. The stock selection drove the underperformance of the Strategy in the quarter. The strategy’s emphasis on […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 6, 2026

The past five years for BioHarvest Sciences (NASDAQ:BHST) investors has not been profitable

The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.